HUP0300093A2 - Taxane prodrugs - Google Patents

Taxane prodrugs

Info

Publication number
HUP0300093A2
HUP0300093A2 HU0300093A HUP0300093A HUP0300093A2 HU P0300093 A2 HUP0300093 A2 HU P0300093A2 HU 0300093 A HU0300093 A HU 0300093A HU P0300093 A HUP0300093 A HU P0300093A HU P0300093 A2 HUP0300093 A2 HU P0300093A2
Authority
HU
Hungary
Prior art keywords
polyethylene glycol
oligomers
taxane
salt
taxane prodrugs
Prior art date
Application number
HU0300093A
Other languages
English (en)
Inventor
Gary S Bartley
Nnochiri N Ekwuribe
Christopher H Price
Original Assignee
Nobex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobex Corp filed Critical Nobex Corp
Publication of HUP0300093A2 publication Critical patent/HUP0300093A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány általában taxán prodrugokat nyújt, amelyek legalább egy,hidrolizálható kötés(ek)sel egy vagy több polietilén-glikololigomerhez kapcsolódó taxánból állnak, az oligomerek 1-25 polietilén-glikol-egységből álló, egyenes vagy elágazó láncú polietilén-glikololigomereket, és adott esetben egy sóképző csoportot tartalmazócsoportból választhatók. A polietilén-glikol oligomer előnyösen egysóképző csoportot tartalmaz, amely előnyösen ammónium- éskarboxilátcsoport közül választható. Ó
HU0300093A 1999-09-13 2000-09-07 Taxane prodrugs HUP0300093A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15357999P 1999-09-13 1999-09-13
US09/476,974 US6380405B1 (en) 1999-09-13 1999-12-31 Taxane prodrugs
PCT/US2000/024523 WO2001019407A2 (en) 1999-09-13 2000-09-07 Taxane prodrugs

Publications (1)

Publication Number Publication Date
HUP0300093A2 true HUP0300093A2 (en) 2003-05-28

Family

ID=26850672

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300093A HUP0300093A2 (en) 1999-09-13 2000-09-07 Taxane prodrugs

Country Status (16)

Country Link
US (1) US6380405B1 (hu)
EP (1) EP1214096A2 (hu)
JP (1) JP2003509386A (hu)
KR (1) KR20020082458A (hu)
CN (1) CN1390142A (hu)
AU (2) AU784395B2 (hu)
BR (1) BR0013949A (hu)
CA (1) CA2384646A1 (hu)
CZ (1) CZ2002929A3 (hu)
HK (1) HK1046856A1 (hu)
HU (1) HUP0300093A2 (hu)
IL (1) IL148559A0 (hu)
MX (1) MXPA02002711A (hu)
NO (1) NO20021212L (hu)
PL (1) PL354779A1 (hu)
WO (1) WO2001019407A2 (hu)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
AU2001252711A1 (en) * 2000-04-15 2001-10-30 Byung-Wook Jo Aqueous-prodrug compound comprising moiety of paclitxel or derivatives thereof, method of preparing same and pharmaceutical composition comprising same
EP2939696B1 (en) 2001-10-18 2016-03-09 Nektar Therapeutics Polymer conjugates of opioid antagonists
US6593334B1 (en) 2002-05-02 2003-07-15 The University Of North Carolina At Chapel Hill Camptothecin-taxoid conjugates as antimitotic and antitumor agents
GR1004274B (el) * 2002-07-16 2003-06-23 Medexis ���� Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
CN1678296A (zh) * 2002-07-30 2005-10-05 卡里凯昂公司 依泽替米贝的组合物和治疗胆固醇有关的良性与恶性肿瘤的方法
AU2003303090A1 (en) * 2002-08-16 2004-08-13 University Of Massachusetts Pyridine and related ligand compounds, functionalized nanoparticulate composites and methods of preparation
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
WO2004043396A2 (en) * 2002-11-09 2004-05-27 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
TWI343816B (en) 2003-07-23 2011-06-21 Novartis Ag Use of calcitonin in osteoarthritis
CA2542351A1 (en) * 2003-11-19 2005-06-02 Novogen Research Pty Ltd. Combinational radiotherapy and chemotherapy compositions and methods
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
NZ583573A (en) * 2003-12-16 2011-12-22 Nektar Therapeutics Pegylated naloxol
DK1720540T3 (da) 2004-02-18 2008-10-06 Gpc Biotech Ag Satraplatin til behandling af resistente tumorer eller tumorer, der er vanskelige at behandle
DE602005018043D1 (de) * 2004-05-17 2010-01-14 Tekmira Pharmaceuticals Corp Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
EP2027853A3 (en) 2004-06-18 2011-01-05 Agennix USA Inc. Kinase inhibitors for treating cancers
US8329958B2 (en) 2004-07-02 2012-12-11 Biocon Limited Combinatorial synthesis of PEG oligomer libraries
US20060135468A1 (en) 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
CA2581125C (en) 2004-09-22 2013-04-23 Nippon Kayaku Kabushiki Kaisha Modified poly(ethylene oxide-amino acid) copolymer, micelle preparation, and anticancer agent containing the same
WO2006042056A2 (en) * 2004-10-08 2006-04-20 The Ohio State University Methods and compositions for enzyme-specific activation of carbohydrate-conjugated prodrugs
CN100361985C (zh) * 2004-10-26 2008-01-16 中国科学院长春应用化学研究所 可生物降解聚合物的紫杉醇前药及其合成方法
EP2138164A1 (en) * 2005-06-17 2009-12-30 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
CN1895676B (zh) * 2005-07-14 2010-11-10 上海艾力斯医药科技有限公司 聚乙二醇为载体的紫杉醇或多烯紫杉醇的前药
CN101309674A (zh) 2005-11-17 2008-11-19 诺瓦提斯公司 药物组合物
CN100431610C (zh) * 2006-01-24 2008-11-12 中国科学院长春应用化学研究所 两亲性三嵌段共聚物-紫杉醇键合药及其制备方法
US8323669B2 (en) 2006-03-28 2012-12-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
US8940332B2 (en) 2006-05-18 2015-01-27 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
US8188222B2 (en) 2006-11-08 2012-05-29 Nippon Kayaku Kabushiki Kaisha High molecular weight derivative of nucleic acid antimetabolite
US8318795B2 (en) * 2007-03-01 2012-11-27 Cedars-Sinai Medical Center Antioxidant polymers containing [1,2]-dithiolane moieties and uses thereof
US7776827B2 (en) * 2007-07-27 2010-08-17 Immuneregen Biosciences, Inc. Method of using substance P analogs for treatment amelioration of myelodysplastic syndrome
JP5349318B2 (ja) 2007-09-28 2013-11-20 日本化薬株式会社 ステロイド類の高分子結合体
US9028874B2 (en) * 2008-01-03 2015-05-12 Cedars-Sinai Medical Center Antioxidant nanosphere comprising [1,2]-dithiolane moieties
WO2009116509A1 (ja) 2008-03-18 2009-09-24 日本化薬株式会社 生理活性物質の高分子結合体
WO2009136572A1 (ja) 2008-05-08 2009-11-12 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
WO2009148698A1 (en) * 2008-06-02 2009-12-10 Cedars-Sinai Medical Center Nanometer-sized prodrugs of nsaids
KR101493125B1 (ko) 2008-11-24 2015-02-12 세다르스-신나이 메디칼 센터 항산화성 캠토테신 유도체 및 이들의 항산화성 항종양성 나노구체
JP2012520314A (ja) 2009-03-11 2012-09-06 アムビト ビオスシエンセス コルポラチオン 癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
CN102421827B (zh) 2009-05-15 2014-07-30 日本化药株式会社 具有羟基的生理活性物质的高分子结合体
US9012469B2 (en) 2010-09-30 2015-04-21 Astrazeneca Ab Crystalline naloxol-peg conjugate
CA2816997A1 (en) 2010-11-17 2012-05-24 Nippon Kayaku Kabushiki Kaisha Novel polymer derivative of cytidine metabolic antagonist
US9359376B2 (en) * 2011-04-08 2016-06-07 Sphaera Pharma Pte. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
CN102276826B (zh) * 2011-06-03 2013-01-02 中国科学院长春应用化学研究所 抗肿瘤前药及其制备方法
BR112014005452B1 (pt) 2011-09-11 2021-03-16 Nippon Kayaku Kabushiki Kaisha método de produção de copolímero de bloco

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5407683A (en) 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
AU6400094A (en) 1993-03-09 1994-09-26 Enzon, Inc. Taxol polyalkylene oxide conjugates of taxol and taxol intermediates
JPH0782291A (ja) 1993-09-13 1995-03-28 Microbial Chem Res Found 水溶性アンスラサイクリン誘導体
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5824701A (en) * 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1997033552A1 (en) 1996-03-12 1997-09-18 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
EP0895784B1 (en) 1996-04-15 2005-11-23 Asahi Kasei Kabushiki Kaisha Drug complexes comprising taxane compounds or steroids
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
SK182599A3 (en) 1997-06-20 2000-07-11 Baker Norton Pharma Soluble prodrugs of paclitaxel
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
CA2291066A1 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Local delivery of long lasting therapeutic agents
JP2002542304A (ja) 1999-04-28 2002-12-10 ベクトレイムド インコーポレイテッド 酵素的に活性化された重合薬物接合体
MXPA02001857A (es) 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs

Also Published As

Publication number Publication date
JP2003509386A (ja) 2003-03-11
WO2001019407A2 (en) 2001-03-22
US6380405B1 (en) 2002-04-30
NO20021212L (no) 2002-05-13
PL354779A1 (en) 2004-02-23
WO2001019407A3 (en) 2002-01-17
NO20021212D0 (no) 2002-03-12
MXPA02002711A (es) 2002-07-30
BR0013949A (pt) 2002-05-14
HK1046856A1 (zh) 2003-01-30
CZ2002929A3 (cs) 2002-08-14
AU784395B2 (en) 2006-03-23
AU2006202613A1 (en) 2006-07-13
CA2384646A1 (en) 2001-03-22
KR20020082458A (ko) 2002-10-31
EP1214096A2 (en) 2002-06-19
IL148559A0 (en) 2002-09-12
CN1390142A (zh) 2003-01-08
AU6951200A (en) 2001-04-17

Similar Documents

Publication Publication Date Title
HUP0300093A2 (en) Taxane prodrugs
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
HUP0004529A3 (en) Sulfonilated dipeptide-compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
DK0886474T4 (da) Karameller indeholdende et södemiddel
IT1293847B1 (it) Dispositivo di protezione per i molari di atleti
DE69324305D1 (de) Zyklische Adhäsionsinhibitoren
ATE131827T1 (de) Verbindungen und verfahren zur unterdrückung der genexpression
ES2160949T3 (es) Derivados de fenilen-sulfonamida sustituidos en meta.
EP1398028A3 (en) Taxanes having alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing same
HUP0301817A2 (hu) Kahalalid-vegyületek, elżállításukra szolgáló eljárás, azokat tartalmazó gyógyászati készítmények és alkalmazásuk
DE69328025T2 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
HUP0100177A2 (hu) Növelt mennyiségű szacharózt tartalmazó, keményítő nélküli Pisum sativum változat
BR9205853A (pt) Composiçoes de revestimento rigido curavel por UV e processos.
DE69406766D1 (de) Polyoxymetalate-Gruppen enthaltende Organosiloxan-Zusammensetzungen
EP0656408A3 (en) Compositions for joining organosiloxane elastomers to organic polymers.
DE69402201D1 (de) Phosphorhaltiges, metallurgisches silizium zur herstellung von organohalosilanen
IL108836A (en) C9 taxane derivatives and pharmaceutical compositions containing them
PT1217898E (pt) Caramelos duros com estabilidade de armazenamento melhorada
SE9502259L (sv) Oligonukleotider för att inhibera expression av isoprenylproteintransferas
DE60104128D1 (de) Alpha-(1,4) glukose-polymer enthaltende oral-zusammensetzungen zur linderung oder verhinderung von zahnschäden
ES2102334T3 (es) Productos cosmeticos.
HUP0200529A2 (en) Optically pure camptothecin analogues, pharmaceutical compositions containing them and their use
FI943176A (fi) Uudet, olefiiniryhmät sisältävät silikoonipolymeerit, niiden valmistusmenetelmä sekä mainitut polymeerit sisältävät kovettuvat koostumukset
HUP0105189A2 (hu) Szervvédő oldatok és alkalmazásuk